23 Feb Avectas
Michael Maguire, Ph.D., CEO
Avectas is a cell engineering company that has pioneered – SOLUPORE® – a proprietary simple, highly effective automated transfection system to enable efficient and safe genetic modification, accelerating the manufacture of cells for the next generation of immuno-oncology therapies. Combined with technical and regulatory support, the company is partnering its cGMP aligned SOLUPORE® clinical-grade system with cell therapy companies to address emerging cell delivery challenges associated with multiple cell modifications and engineering of cells that are limited or fragile. Avectas is a private, international company with research facilities in Dublin, as well as an office in Cambridge MA, USA. It has over 35 employees and is led by a team of highly experienced pharmaceutical executives, who are supported by a world-class Scientific Advisory Board of cancer cell therapy experts. The Company has raised over US$50m to date.